Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-21
2010-12-28
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S188000
Reexamination Certificate
active
07858650
ABSTRACT:
A medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist topically exhibits a prolonged bronchodilating and antiinflammatory effects. Namely, the medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist is useful as a safe preventive and/or a remedy for respiratory diseases (for example, asthma, pulmonary injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, cystic fibrosis, pulmonary hypertension or the like) without causing any systemic effect such as lowering blood pressure. Thus, a safe and useful remedy for respiratory diseases is provided.
REFERENCES:
patent: 4039668 (1977-08-01), Fuchs
patent: 6723713 (2004-04-01), Sequeira
patent: 7402605 (2008-07-01), Tani et al.
patent: 2002/0124577 (2002-09-01), Ferris et al.
patent: 2002/0189610 (2002-12-01), Bozung et al.
patent: 2005/0020686 (2005-01-01), Maruyama
patent: 2009/0042885 (2009-02-01), Tani et al.
patent: 0860430 (1998-08-01), None
patent: 50-047967 (1975-04-01), None
patent: 09-501700 (1997-02-01), None
patent: 2004-517942 (2004-06-01), None
patent: 7704739 (1977-11-01), None
patent: 02/42268 (2002-05-01), None
patent: 03/008377 (2003-01-01), None
patent: WO 03/009872 (2003-02-01), None
patent: WO 03/074483 (2003-09-01), None
patent: WO 2004/065365 (2004-08-01), None
patent: WO 2005/053707 (2005-06-01), None
patent: WO 2005/061492 (2005-07-01), None
Vippagunta et al., Crystalline solids, 2001, Advanced Drug Delivery Reviews, 48, 3-26.
Mitsuo Matsumoto; “Yakuzaigaku Manual”, Nanzando, 1989, pp. 30, 118-119.
Hitoshi Sezaki, “Drug Delivery System”, Nankodo co., Ltd., pp. 49 to 57.
Mitsuru Hashida, “Keiko Toyo Seizai no Sekkei to Hyoka”, Kabushiki Kaisha Yakugyo Jihosha, 1995, pp. 216 to 231.
Burgess, Janette K. et al. “Increased sensitivity of asthmatic airway smooth muscle cells to prostaglandin E2 might be mediated by increase numbers of E-prostanoid receptors” Journal of Allergy and Clinical Immunology, vol. 113, No. 5. May 2004, p. 876-881, XP009123804.
Billot, Xavier et al. “Discovery of a Potent and Selective Agonist of the Prostaglandin EP4 Receptor” Bioorganic & Medicinal Chemistry Letters, Pergamon, Elsevier Science, GB, vol. 13, No. 6, Mar. 24, 2003, p. 1129-1132, XP002471705.
Zoretic, P.A. et al. “Synthesis of (E)-7-[[2-[4-(m-Trifluoromethylphenoxy)-3α and 3β-Hydroxy-1-butenyl]-5-oxo-1-pyrrolidinyl]]heptanoic Acids” Journal of Heterocyclic Chemistry, Heterocorporation, Provo, US. vol. 20, Jan. 1, 1983, p. 465-466, XP002182343.
Extended European Search Report issued in European Patent Application No. 05795486.9-2404 dated Nov. 2.
Kadode Michiaki
Maruyama Toru
Nagase Toshihiko
Shiroya Tsutomu
Tani Kousuke
Bianchi Kristin
Ono Pharmaceutical Co. Ltd.
Saeed Kamal A
Sughrue & Mion, PLLC
LandOfFree
Medicinal composition for inhalation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicinal composition for inhalation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicinal composition for inhalation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4181131